Senna–docusate

Selected Senna-S tablets contain sennosides 8.6 mg and docusate sodium 50 mg. Drug Facts lists relief of occasional constipation and a usual bowel movement in 6–12 hours. Ongoing constipation, opioid-related regimens, bowel preparation, and other product strengths require a separate clinician plan; do not assume an occasional-use label proves all those uses.

This selected product is listed as an OTC monograph drug with M007 metadata, not a dietary supplement or a product-specific FDA-approved application. Its label states that FDA has not evaluated compliance. OTC monograph marketing depends on applicable requirements; the listed category is not independent certification of this particular combination.

AGA/ACG conditionally suggests senna for adult chronic idiopathic constipation with low-certainty evidence; that recommendation does not prove added benefit from docusate. A 10-day randomized hospice trial found no significant benefit from adding docusate to sennosides. That narrow population/result does not establish equivalence for every patient, dose, or product.

Take orally, preferably at bedtime or as directed by a doctor. Do not exceed the selected label maximum, and do not use laxatives longer than 1 week without medical direction. Each whole tablet contributes both ingredients; an adult maximum of 8 tablets/day totals sennosides 68.8 mg and docusate sodium 400 mg. Lower age limits are below; do not transpose this table to another concentration or senna-only product.

Do not escalate beyond the package limit when a bowel movement does not occur. Stop and seek clinical assessment for failure to have a bowel movement after use or rectal bleeding. A clinician-directed longer regimen is distinct from OTC self-treatment; no universal chronic combination dose or taper is established here.

This OTC Drug Facts label has no prescription-style numbered contraindications section. Its explicit do-not-use directions cover current mineral-oil use and laxative use beyond 1 week unless a doctor directs otherwise. Abdominal pain/nausea/vomiting and persistent bowel-habit changes require assessment before use; absence of a formal section is not a claim that use is safe in every intestinal disorder.

The selected OTC label has no boxed warning. Drug Facts warnings and pediatric dose limits still apply; “natural” does not remove those instructions.

Senna can cause abdominal pain/cramping, particularly at higher doses; its longer-term safety evidence is limited. The combination Drug Facts does not provide a quantified adverse-event catalog or a detailed overdose antidote. For excessive ingestion, contact medical/poison services immediately and report the exact product, amount, and timing. No home antidote or invented adverse-event incidence is supplied.

Do not use while taking mineral oil unless a doctor directs it. The combination label supplies no safe spacing interval or dose adjustment that removes that warning; do not invent one.

The selected label does not give a comprehensive interaction study set. Review other senna/sennoside, docusate, and laxative products so the exact ingredient totals and maximum are understood. Chronic prescribed bowel regimens and medicines that cause constipation need individualized review rather than an unsupported universal interaction list or spacing rule.

The selected Drug Facts directs pregnant or breastfeeding patients to ask a health professional before use. It does not establish a pregnancy dose, quantify infant exposure, or prove absence of reproductive risk. Do not interpret botanical origin or OTC status as independent pregnancy/lactation safety evidence.

Use the selected age-specific table; under 2 requires a doctor. The young-child half-tablet direction requires an accurately deliverable dose with the actual dispensed product. No separate geriatric regimen or frailty study is supplied by Drug Facts; persistent symptoms and tolerance need clinical review instead of automatically using the maximum.

Drug Facts supplies no quantitative kidney/liver adjustment algorithm or organ-impairment pharmacokinetic study. This is an evidence limitation, not proof that every stage of disease permits unrestricted use. Clinician-directed selection and follow-up are appropriate when comorbidity, symptoms, or longer use requires assessment.

Drug Facts identifies sennosides as a laxative and docusate sodium as a stool softener. These purposes describe different roles; they do not themselves prove that the fixed combination is more effective than senna alone. Detailed molecular claims for docusate are not inferred from its product purpose.

The original guideline describes gut-microbial conversion of sennosides into active metabolites that influence colonic secretion and movement. The selected combination label supplies a 6–12-hour response window but no product-specific serum half-life, bioavailability, clearance, or renal/hepatic PK study. Those quantities are not invented or borrowed from an unrelated formulation.

Track bowel movement response, abdominal symptoms, rectal bleeding, dose totals, and treatment duration. Stop and seek care for failure to respond or bleeding; consult before use for persistent changes or stomach pain/nausea/vomiting. The OTC label supplies no routine laboratory interval for otherwise uncomplicated occasional use and no universal chronic monitoring algorithm.

Verify both ingredient strengths, use the age-specific start, and respect the maximum. Bedtime use may produce a bowel movement overnight; do not take extra doses simply because response is not immediate. Consult before combining with mineral oil or using longer than 1 week. Ask a professional during pregnancy/breastfeeding, keep away from children, and contact medical/poison services promptly for overdose.

Aarkish Pharmaceuticals NJ Inc. Senna-S is the selected film-coated tablet product, NDC 81005-102. SPL package records list 300-count bottle 81005-102-30 and 1,000-count bottle 81005-102-10. The source does not establish a reliable tablet imprint/color description, so none is invented. Senokot-S comparison wording does not make this a manufacturer-identical brand product.

Each covered oral tablet contains sennosides 8.6 mg and docusate sodium 50 mg. Other combination strengths, softgels, senna-only liquid/tablets, docusate-only products, botanical supplements, and suppositories are outside scope; do not convert them tablet-for-tablet.

Store at 25°C, with permitted excursions 15–30°C. Do not use if the printed seal beneath the cap is missing or broken. Each tablet lists calcium 4 mg and sodium 8 mg. Keep out of children’s reach; no unsupported opened-bottle expiry or freezing instruction is supplied.